Lansoprazole Dosage

Medically reviewed by Drugs.com. Last updated on Feb 2, 2024.

Usual Adult Dose for Erosive Esophagitis

Treatment: 30 mg orally once a day

• Duration of therapy: Up to 8 weeks

Maintenance: 15 mg orally once a day

Comments:

• Controlled maintenance studies did not extend beyond 12 months.
• If patients are not healed after 8 weeks OR if erosive esophagitis recurs, treatment for another 8 weeks may be considered.

Uses:

• Short-term treatment for healing and symptom relief of all grades of erosive esophagitis
• Maintain healing of erosive esophagitis

Usual Adult Dose for Duodenal Ulcer

Treatment: 15 mg orally once a day

• Duration of therapy: Up to 4 weeks

Maintenance: 15 mg orally once a day

Comment: Controlled maintenance studies did not extend beyond 12 months.

Uses:

• Short-term treatment for healing and symptom relief of active duodenal ulcers
• Maintain healing of duodenal ulcers

Usual Adult Dose for Duodenal Ulcer Prophylaxis

Treatment: 15 mg orally once a day

• Duration of therapy: Up to 4 weeks

Maintenance: 15 mg orally once a day

Comment: Controlled maintenance studies did not extend beyond 12 months.

Uses:

• Short-term treatment for healing and symptom relief of active duodenal ulcers
• Maintain healing of duodenal ulcers

Usual Adult Dose for Duodenal Ulcer Maintenance

Treatment: 15 mg orally once a day

• Duration of therapy: Up to 4 weeks

Maintenance: 15 mg orally once a day

Comment: Controlled maintenance studies did not extend beyond 12 months.

Uses:

• Short-term treatment for healing and symptom relief of active duodenal ulcers
• Maintain healing of duodenal ulcers

Usual Adult Dose for Gastroesophageal Reflux Disease

15 mg orally once a day

• Duration of therapy: 14 days (over-the-counter [OTC] formulations); up to 8 weeks (prescription formulations)

Comments:

• Treatment may take 1 to 4 days for full effect; this drug should not be used for immediate heartburn relief.
• Patients may repeat an OTC course of treatment every 4 months.

Uses:

• Treatment of frequent heartburn occurring at least 2 days a week (OTC formulations)
• Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)

Usual Adult Dose for Gastric Ulcer

30 mg orally once a day

• Duration of therapy: Up to 8 weeks

Use: Short-term treatment for healing and symptom relief of active benign gastric ulcers

Usual Adult Dose for Multiple Endocrine Adenomas

Initial dose: 60 mg orally once a day
Maintenance dose: 60 to 180 mg/day

Comments:

• A daily dose higher than 120 mg should be given as divided doses.
• Doses should be patient-specific and should continue as long as clinically necessary. Some patients with Zollinger-Ellison syndrome (ZES) have been on treatment for longer than 4 years.

Use: Long-term treatment of pathological hypersecretory conditions, including ZES with/without multiple endocrine adenomas

Usual Adult Dose for Systemic Mastocytosis

Initial dose: 60 mg orally once a day
Maintenance dose: 60 to 180 mg/day

Comments:

• A daily dose higher than 120 mg should be given as divided doses.
• Doses should be patient-specific and should continue as long as clinically necessary. Some patients with Zollinger-Ellison syndrome (ZES) have been on treatment for longer than 4 years.

Use: Long-term treatment of pathological hypersecretory conditions, including ZES with/without multiple endocrine adenomas

Usual Adult Dose for Zollinger-Ellison Syndrome

Initial dose: 60 mg orally once a day
Maintenance dose: 60 to 180 mg/day

Comments:

• A daily dose higher than 120 mg should be given as divided doses.
• Doses should be patient-specific and should continue as long as clinically necessary. Some patients with Zollinger-Ellison syndrome (ZES) have been on treatment for longer than 4 years.

Use: Long-term treatment of pathological hypersecretory conditions, including ZES with/without multiple endocrine adenomas

Usual Adult Dose for Helicobacter pylori Infection

Triple Therapy: 30 mg orally 2 times a day, taken concomitantly with amoxicillin and clarithromycin

• Duration of therapy: 10 to 14 days

Dual Therapy: 30 mg orally 3 times a day, taken concomitantly with amoxicillin

• Duration of therapy: 14 days

Comments:

• Refer to the manufacturer product information for dosing for amoxicillin and/or clarithromycin.
• Eradication of Helicobacter pylori has been shown to reduce duodenal ulcer recurrence, and may result in duodenal/gastric ulcer healing without the need for continued therapy.

Uses:

• Triple therapy: In combination with amoxicillin and clarithromycin for the treatment of patients with H pylori infection and duodenal ulcer disease (active/1-year history of a duodenal ulcer) to eradicate H pylori
• Dual therapy: In combination with amoxicillin for the treatment of patients with H pylori infection and duodenal ulcer disease (active/1-year history of a duodenal ulcer) who are either allergic/intolerant to clarithromycin OR in whom resistance to clarithromycin is known/suspected

Usual Adult Dose for NSAID-Induced Gastric Ulcer

30 mg orally once a day

• Duration of therapy: Up to 8 weeks

Comment: Treatment studies did not extend beyond 8 weeks.

Use: Treatment of NSAID-associated gastric ulcer in patients who continue NSAID use

Usual Adult Dose for NSAID-Induced Ulcer Prophylaxis

15 mg orally once a day

• Duration of therapy: Up to 12 weeks

Comment: Prophylaxis studies did not extend beyond 12 weeks.

Use: Reducing the risk of NSAID-associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an NSAID

Usual Pediatric Dose for Gastroesophageal Reflux Disease

1 to 11 years:

• Less than or equal to 30 kg: 15 mg orally once a day
• Greater than 30 kg: 30 mg orally once a day
• Duration of therapy: Up to 12 weeks

12 years and older: 15 mg orally once a day

• Duration of therapy: Up to 8 weeks

Uses:

• Short-term treatment of GERD and other symptoms associated with GERD
• Short-term treatment of symptomatic, non-erosive GERD

Usual Pediatric Dose for Erosive Esophagitis

1 to 11 years:

• Less than or equal to 30 kg: 15 mg orally once a day
• Greater than 30 kg: 30 mg orally once a day
• Duration of therapy: Up to 12 weeks

12 to 17 years: 30 mg orally once a day

• Duration of therapy: Up to 8 weeks

Use: Short-term treatment for healing and symptom relief of all grades of erosive esophagitis

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

Mild to moderate liver dysfunction (Child-Pugh Class A to B): No adjustment recommended.
Severe liver dysfunction (Child-Pugh Class C): 15 mg orally once a day

Dose Adjustments

Patients receiving high-dose methotrexate: Temporary withdrawal of this drug should be considered.

Precautions

CONTRAINDICATIONS:

• Known severe hypersensitivity to the active component or any of the ingredients
• Use with rilpivirine-containing products

For the treatment of H pylori (as combination therapy): Refer to the contraindications section of the other antibacterial agents for further information.

Safety and efficacy of prescription formulations have not been established in patients younger than 1 year.

Safety and efficacy of over-the-counter formulations have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• This drug should be taken prior to eating and should not be crushed/chewed. Ideally, this drug should be taken in the morning, 30 minutes prior to breakfast.
• The oral dissolvable tablet should be placed on the tongue and allowed to disintegrate.
• The delayed-release capsule may be opened and sprinkled onto a tablespoon of applesauce, pudding, cottage cheese, yogurt, or strained pears and swallowed immediately. Do not chew or crush granules. Alternatively, it may also be emptied into a small volume (60 mL) of either apple juice, orange juice or tomato juice and swallowed immediately. Rinse glass with more juice and swallow immediately.
• This drug may be mixed with apple juice and administered via nasogastric tube.

Storage requirements:

• The manufacturer product information should be consulted.

Reconstitution/preparation techniques:

• The manufacturer product information should be consulted.

General:

• Children younger than 1 year of age did not show beneficial effects when treated for gastroesophageal reflux disease.
• H pylori eradication rates reach 90% when this drug is combined with clarithromycin and amoxicillin/metronidazole. Lower eradication rates were seen in the combination of this drug, amoxicillin, and metronidazole.
• Treatment should be given at least an hour prior to sucralfate or antacids.
• A single, 30 mg dose inhibited stimulated acid secretion by 30%; after repeated dosing over 7 days, 90% of stimulated acid secretion was inhibited.

Monitoring:

• METABOLIC: Magnesium levels, especially in patients taking other drugs that could result in hypomagnesemia or those on long-term therapy
• METABOLIC: Vitamin B12 levels, especially in patients on long-term therapy
• MUSCULOSKELETAL: Bone fractures, especially in patients at high risk for osteoporosis-related events

Patient advice:

• If using this drug to treat H pylori, tell patients that it is important to complete the full regimen.
• Instruct patients to seek medical attention if signs/symptoms of hypersensitivity, Clostridium difficile, or systemic cutaneous lupus erythematosus occur.
• Inform patients that this drug may cause drowsiness, somnolence, dizziness, vertigo, and/or visual disturbances. They should avoid driving or operating machinery until the full effects of the drug are seen.
• Advise patients to speak to their healthcare provider if they become pregnant, intend to become pregnant, or are breastfeeding.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer